Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions.
Our first product candidate, NeoCart, leverages our regenerative medicine platform to provide an innovative treatment in the orthopaedic space, specifically cartilage damage in the knee. NeoCart® is currently enrolling a Phase 3 clinical trial in the United States under a Special Protocol Assessment with the U.S. Federal Drug Administration (FDA). If the study is successful and NeoCart® is approved, we believe it would be the first product approved for the first-line treatment of severe cartilage damage to demonstrate clinical superiority over the current standard of care, microfracture.
Please visit our website at http://www.Histogenics.com for more information about our company.